Trump threatens to push 200% pharma tariffs, pushing drugs, hit the hits

The drug industry, the 200% tariff offer of US President Donald Trump threatens to drive drug prices and remove corporate gain margins.

President He once again warned The long-awaited industrial tariffs will be announced on Tuesday “Too soon” Launched a named after administration after 232 Investigation In April to the sector.

Trump suggested that these taking will not be taken into force immediately, but one year and one-half years of entering a year and one and a half years.

Nevertheless, with the delay of such a ratio, such an exchange rate will be harmful to drug prices and profit.

“200% tariff violations of the risk supply chain and a risk supply chain, which are higher prices for pottery and risk supply chain, medicinal failure and higher prices for US consumers,” Barclays, Celebrated Wednesday.

UBS analysts showed a “significant negative impact” called “significant negative impact” on the edges of the United States, which can be “disastrous”.

“It would be potentially catastrophic for everyone, because we need these pharmaceuticals, and these companies have long been close to production in the United States,” Beschloss CNBC has been closed. “

In addition to a total of 25% of the pharmaceutical imports, the US drug prices for about $ 51 billion each year, while internal prices increased by 12.9%, according to Pharmaceutical researchers and manufacturers of presidential security (PHRMA) are conducting research as “counter-results” as “counter-float” as “counter-float” on Wednesday.

In response to this, Global Pharma firms – including Novartis, Sanofi and Roche and the headquarters of the United States Eli lilli and Johnson & Johnson – The United States has developed liabilities to spend large amounts

As the “insufficient time” for companies to transfer the production situations of the UBS management, the department “deficiency” was 12-18 months.

“We usually consider the schedule for a new place to relocate the graphically after 5 years,” we wrote analysts.

At the end of this month, it is waiting for more information about the 232 investigative report. However, in this time, companies have another choice to plan for various potential.

A roche spoke voyage said the company’s “closely watch the situation” and “supporters of policies that prevent impatience” and “a more fair and affordable health ecosystem”.

Switzerland’s pharmacy giant previously said that Trump’s drug assessment order could endanger the US investment. However, the proposed funding offered on Wednesday noted that it allows it to continue production in the United States

Bayer said that the same way that “different tariff ads” and to provide supply chains and “minimize any potential impact”.

Meanwhile, Novartis, US Management and Commonwealth Union continued to work with partners and said that it is planned to be planned, “no change”.

AstraRazeneca and Sanofi immediately responded to CNBC’s desire, Novo Nordisk refused to comment on the income process before the income.

The pharmaceutical industry had previously searched for sector width of the tariffs. However, as these hopes faded, the attention is already becoming promising trade transactions such as potential buff.

The UK trade deal in the United Kingdom, sparse in the last month, stamp This is both parties, “Britain’s pharmaceutical and pharmaceutical results were founded on the results of discounted treatment and findings of a part of pharmaceutical substances, 232 investigations.

Pharma firms in Switzerland and the European Union, may target similar caravations in promising transactions. Again, without clarity, the question marks for companies and consumers will soon remain.

“This uncertainty will be affected by which sectors will be affected and affect and a sustainable negative impact,” Berti Colijn “in the European Early Edition” Ing